AUG 14, 2026 · PHASE 3 TRIAL
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
ClinicalTrials.gov
This is a Phase 3 trial registration with no posted results; the study is actively recruiting and outcome data are not yet available for evaluation.
Reported
Planned enrollment780
PhasePhase 3
Primary outcome measureDisease-free survival (DFS) as assessed by…